T F Reiss

What are minimal important changes for asthma measures in a clinical trial?

J Zhang, N. Santanello, T. Reiss, 1999, The European respiratory journal.

Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma.

J Zhang, T. Reiss, G. Noonan, 1996, The Journal of allergy and clinical immunology.

Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma.

J. Kemp, R. Dockhorn, T. Reiss, 1998, The Journal of pediatrics.

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group.

R. Dockhorn, T. Reiss, S Shingo, 1998, Archives of internal medicine.

Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids.

J Zhang, W. Busse, C. Sorkness, 1997, Thorax.

Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.

L Hendeles, J. Kemp, R. Dockhorn, 1998, The New England journal of medicine.